|

Fluorouracil Clinical Trials

55 actively recruiting trials across 25 locations

▼ -1 trial since August 2026

Also known as: 2,4-Dioxo-5-fluoropyrimidine, 5 FU, 5 Fluorouracil, 5 Fluorouracilum, 5-FU +22 more

Pipeline

Phase 1: 14Phase 2: 16Phase 3: 14Phase 1/2: 7Phase 2/3: 3

Top Sponsors

  • National Cancer Institute (NCI)4
  • Astellas Pharma Global Development, Inc.4
  • Sun Yat-sen University3
  • M.D. Anderson Cancer Center3
  • Sichuan Baili Pharmaceutical Co., Ltd.2

Indications

  • Cancer55
  • Stage IV Pancreatic Cancer AJCC v85
  • Stage IV Colorectal Cancer AJCC v85
  • Liver Cancer5
  • Metastatic Pancreatic Adenocarcinoma4

Other18 trials

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Phase 1
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Phase 3
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Phase 3
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Phase 1/2
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3
AB122 Platform Study
Phase 1
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Phase 2
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Phase 2
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Phase 3
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Phase 2
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Phase 2/3
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Phase 1/2
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
Phase 2
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Phase 2/3
The Sagittarius Trial
Phase 3
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Phase 2/3

Duarte, California6 trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

City of Hope National Medical Center /ID# 270255

Phase 2
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

City of Hope Medical Center

Phase 2
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Birmingham, Alabama4 trials

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

O Neal Comprehensive Cancer Center at UAB

Phase 1/2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

University of Alabama at Birmingham Cancer Center

Phase 3

Houston, Texas3 trials

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

M D Anderson Cancer Center

Phase 2
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M D Anderson Cancer Center

Phase 1
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

M D Anderson Cancer Center

Phase 1/2

Anchorage, Alaska2 trials

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Anchorage Associates in Radiation Medicine

Phase 3

Los Angeles, California2 trials

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Fairbanks, Alaska1 trial

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Fairbanks Memorial Hospital

N/A

Gilbert, Arizona1 trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Banner MD Anderson Cancer Center

Phase 3

Glendale, Arizona1 trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3

Phoenix, Arizona1 trial

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2

Scottsdale, Arizona1 trial

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

HonorHealth Research Institute

Phase 1

Tucson, Arizona1 trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

University of Arizona Cancer Center - North Campus

Phase 3

Fayetteville, Arkansas1 trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Highlands Oncology Group - Fayetteville

Phase 2

Fort Smith, Arkansas1 trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Mercy Hospital Fort Smith

Phase 3

Irvine, California1 trial

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1

Orange, California1 trial

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1

Santa Barbara, California1 trial

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Samsun Clinic - Ridley-Tree Cancer Center

Phase 3

Whittier, California1 trial

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Innovative Clinical Research Institute

Phase 3

New Haven, Connecticut1 trial

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Yale University Cancer Center

Phase 1

Gainesville, Florida1 trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

UF Health Cancer Institute - Gainesville

Phase 1

Atlanta, Georgia1 trial

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

Emory University Hospital Midtown

Phase 2

Chicago, Illinois1 trial

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2

Rochester, Minnesota1 trial

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Mayo Clinic in Rochester

Phase 1/2

Buffalo, New York1 trial

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Roswell Park Cancer Institute

Phase 1/2

Lake Success, New York1 trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.